Plasma amyloid-beta levels as a biomarker for prodromal Alzheimer’s Disease

Takeaway

  • Amyloid-beta (Aβ) peptides in the plasma could be a reliable biomarker for discriminating Aβ- positron emission tomography (PET) status to facilitate screening for prodromal Alzheimer’s disease (AD) clinical trials.

Why this matters

  • Healthy people at risk of AD are needed for clinical trials of preventative therapies.

  • These people are difficult to identify owing to lack of amyloid-beta positive PET scan, highlighting a need for accessible and inexpensive screening tools.